Previous 10 | Next 10 |
home / stock / sny / sny articles
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected ...
Sanofi SA (NASDAQ:SNY) says its fourth-quarter operating income fell 5.2% to €2.6 billion, up 5.3% on constant currency. Revenues ...
With the Fed decision now in the rearview mirror, sentiment appears to have taken a turn for the better on the hopes of receiving strong earnings r...
The past week’s earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that woul...
Thursday, the FDA approved Regeneron Pharmaceutical Inc (NASDAQ:REGN) / Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for...
Sanofi SA (NASDAQ:SNY) has agreed to acquire assets and liabilities associated with Inhibrx Inc’s (NASDAQ:INBX) INBRX-101, an ...
In a strategic move to bolster its rare disease business, Sanofi SA (NASDAQ:SNY) has agreed to acquire the drug development project INBRX-101 from ...
HC Wainwright has downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS). Earlier this month, the company released topline results from its Ph...
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in a...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...
2024-06-09 09:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...